id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2004-E-0397-0005,FDA,FDA-2004-E-0397,Determination of Regulatory Review Period for Purposes of Patent Extension; RESTYLANE,Notice,General Notice,2006-08-07T04:00:00Z,2006,8,2006-06-12T04:00:00Z,2006-08-15T03:59:59Z,2025-11-12T18:17:39Z,,0,0,09000064804743df
FDA-2004-E-0397-0003,FDA,FDA-2004-E-0397,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-05-25T04:00:00Z,2006,5,,,2025-11-12T18:05:41Z,,0,0,09000064804743dd
FDA-2004-E-0397-0004,FDA,FDA-2004-E-0397,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-05-25T04:00:00Z,2006,5,,,2025-11-12T18:12:16Z,,0,0,09000064804743de
FDA-2004-E-0397-0002,FDA,FDA-2004-E-0397,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-02-28T05:00:00Z,2006,2,,,2025-11-12T18:03:00Z,,0,0,09000064804743dc